Core Viewpoint - Southbound funds have significantly increased their holdings in MicroPort Medical (00853.HK), indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Southbound Fund Activity - On January 23, southbound funds increased their holdings by 1.6216 million shares of MicroPort Medical [1] - Over the past five trading days, there have been four days of net increases, totaling 7.5492 million shares [1] - In the last 20 trading days, there were 16 days of net increases, amounting to 33.0996 million shares [1] - Currently, southbound funds hold 913 million shares of MicroPort Medical, representing a significant portion of the company's issued ordinary shares [1] Group 2: Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Summary of MicroPort Scientific (0853.HK) Conference Call Company Overview - **Company**: MicroPort Scientific (0853.HK) - **Industry**: Medical Devices Key Financial Highlights - **FY25 Profit Alert**: MicroPort announced a net profit of at least US$20 million, a significant improvement compared to a projected loss of US$54 million and a consensus loss of US$57 million. This marks a turnaround from a loss of US$268 million in FY24 [1] - **Revenue Growth**: The growth is primarily driven by the 'going-abroad' business, which saw a year-over-year increase of 70% [1] - **Gross Margin Expansion**: There was an increase in gross margin by 2-3 percentage points [1] - **Operating Expense Reduction**: Operating expenses were reduced by 10-11% [1] Strategic Insights - **Turnaround Strategy**: The results indicate that the company's strategic shift and financial discipline are yielding faster results than anticipated, reinforcing the view that the turnaround story is on track [1] - **Future Guidance**: Management is optimistic about a return to full-year profitability in FY26, supported by continued high growth in the "Going-abroad" platform, which is expected to grow by 70-80% YoY for FY25 [4] Market Position and Valuation - **Target Price**: The target price for MicroPort is set at HK$16.00, representing an expected share price return of 28.4% from the current price of HK$12.46 [2] - **Market Capitalization**: The company has a market cap of HK$23,835 million (approximately US$3,057 million) [2] - **Valuation Breakdown**: The target price is derived from a sum-of-the-parts valuation, including HK$9.5 per share for Vascular, HK$1.6 for Orthopedics, HK$1.7 for Heart Valve, HK$1.8 for CRM, and HK$5.1 for Surgical Robot, minus HK$3.5 per share in net debt [5] Risks and Challenges - **Domestic Policy Headwinds**: The company faces risks from ongoing volume-based procurement (VBP) and Diagnosis-Related Group (DRG) payment reforms in China, which could impact revenue and margins [6] - **Execution Risks**: As MicroPort expands globally, it may encounter execution risks in new markets, regulatory hurdles, and supply chain disruptions [6] - **Geopolitical Tensions**: Global trade frictions and geopolitical tensions could adversely affect international sales, which are critical to the company's growth strategy [6] Conclusion MicroPort Scientific is showing promising signs of recovery with a strong FY25 profit alert, driven by strategic initiatives and operational efficiencies. However, the company must navigate various risks, particularly in its domestic market and during its global expansion efforts. The positive outlook and target price suggest potential for significant share price appreciation in the near term.

Core Viewpoint - MicroPort Medical's stock price surged significantly due to positive earnings expectations, with a projected turnaround to profitability in 2025, anticipating a net profit of at least $20 million after a forecasted net loss of approximately $268 million in 2024 [2][3]. Group 1: Financial Performance - The company has experienced a cumulative net loss of nearly $1.6 billion from 2020 to 2024, indicating significant operational pressure [5]. - The anticipated improvement in profitability for 2025 is attributed to four key factors, including strong performance in overseas business, cost optimization leading to a gross margin increase of 2-3 percentage points, and a reduction in operating expenses by approximately 10-11% [6]. Group 2: Business Strategy and Market Position - MicroPort Medical has established itself as a leading international high-end medical device group in China, with a diversified core business cluster covering critical areas such as cardiovascular intervention, neurointervention, orthopedics, cardiac rhythm management, and surgical robotics [5]. - The company has maintained its leading market share domestically while accelerating the market entry of new products and technologies, enhancing its core competitiveness [5]. - The company is leveraging its overseas channels to expand its international business footprint, integrating resources to facilitate rapid market penetration [5]. Group 3: Future Outlook - Analysts suggest that MicroPort Medical's growth momentum may further accelerate due to the vast growth potential in the global medical device market and the ongoing high-quality development of China's medical industry, alongside the deepening process of domestic medical device substitution [6].

Core Viewpoint - MicroPort Medical (00853) has experienced a significant stock increase of over 11%, currently trading at HKD 13.63 with a transaction volume of HKD 260 million, following the announcement of expected profitability by the end of 2025, with a net profit forecast of no less than USD 20 million [1] Financial Performance - The company anticipates turning a profit for the fiscal year ending December 31, 2025, primarily due to continuous revenue growth, particularly from overseas operations, which are expected to contribute to a year-on-year revenue increase of approximately 70% [1] - Despite downward pressure on product prices from domestic industry policies, the company expects a gross margin improvement of 2-3 percentage points year-on-year, attributed to the implementation of cost optimization measures [1] Operational Efficiency - The company is focused on enhancing operational efficiency through the continuous deepening of lean management practices, which have led to a year-on-year reduction in operating expenses by approximately 10-11% [1] - The disposal of subsidiaries has also contributed positively to the company's financial performance [1]

Core Viewpoint - MicroPort Medical (00853) is expected to turn a profit by the end of 2025, projecting a net profit of no less than $20 million, driven by continuous revenue growth, particularly from overseas business [1] Group 1: Financial Performance - The company anticipates achieving profitability due to sustained revenue growth, with overseas business contributing approximately 70% year-on-year growth [1] - The gross profit margin is expected to increase by 2-3 percentage points year-on-year, despite downward pressure on product prices from domestic industry policies [1] - The operating expenses are projected to decrease by about 10-11% year-on-year due to ongoing lean management initiatives [1] Group 2: Market Reaction - Following the announcement, MicroPort Medical's stock surged over 11%, with a current increase of 9.39%, trading at HKD 13.63 and a transaction volume of HKD 260 million [1] Group 3: Strategic Initiatives - The company has implemented cost optimization measures that have positively impacted its financial performance [1] - The disposal of subsidiaries has also contributed positively to the group's earnings [1]

Group 1 - The core point of the article highlights that southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 3.5917 million shares on January 22, 2026, marking a positive trend in investment interest [1] - Over the past five trading days, southbound funds have increased their holdings on four occasions, with a total net increase of 10.374 million shares [1] - In the last twenty trading days, there have been fifteen days of net increases in holdings, totaling 31.3323 million shares [1] Group 2 - As of January 22, 2026, southbound funds hold a total of 911 million shares of MicroPort Medical, which represents a significant portion of the company's issued ordinary shares [1] - The daily changes in shareholding for the last five trading days show fluctuations, with the largest increase being 4.4877 million shares on January 19, 2026, and a decrease of 2.0648 million shares on January 20, 2026 [2] - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices, operating through eight business segments including cardiovascular intervention, orthopedic medical devices, and surgical robotics [2]

Major Events - UBTECH (09880) plans to invest 300 million yuan to establish a partnership for investments in the smart robotics industry chain [1] - Tian Ge Interactive (01980) received a 1.41% discount from Sina Hong Kong for a partial tender offer to acquire 32.5 million shares, with trading resuming on January 22 [1] - Fosun Pharma (02196) received approval for the drug registration application of heavy tartrate norepinephrine injection [1] - Valiant (09887) received orphan drug designation (ODD) from the European Commission for Valiant™ for the treatment of extra-pulmonary neuroendocrine carcinoma [1] - GCL-Poly Energy (01050) secured orders for AI giant server enclosures, accelerating ASIC business production, and commenced construction of a new base in Thailand [1] - China Rare Earth Holdings (03788) plans to raise approximately 783 million HKD to support the development of the Mt Bundy gold mine project [1] - Nanshan Aluminum International (02610) plans to place 31 million shares, aiming to raise approximately 1.9868 billion HKD [1] - Qiming Medical-B (02500) reported a patent infringement lawsuit against Edwards by Cardiovalve Ltd. and MTH IP, L.P. regarding US Patent No. 385 [1] - Minmetals Resources (01208) expects total copper production of 506,900 tons in 2025, a year-on-year increase of 27% [1] - Prudential (02378) invested approximately 375 million USD to increase its stake in PAMB to 70% [1] - Nocoda Technology (00519) successfully implemented innovative smart handling robots in Hong Kong public housing estates [1] - Idali Holdings (00720) B-ON Global S.àr.l. plans to acquire 1.3 billion shares of the company, becoming the major shareholder [1] Bonds and Notes - China Shipbuilding Leasing (03877) subsidiary plans to issue 2.338 billion HKD convertible bonds [2] Buybacks/Reductions - China Communications Construction (01800) repurchased 1.06837 million HKD worth of 1.2588 million A-shares on January 22 [2] - Kuaishou-W (01024) spent approximately 29.9714 million HKD to repurchase 380,000 shares on January 22 [2] - Xiaomi Group-W (01810) repurchased shares worth 201 million HKD, acquiring 5.7138 million shares on January 22 [2] - Xiaomi Group-W (01810) plans to repurchase up to 2.5 billion HKD of Class B ordinary shares [2] - Sanhua Intelligent Control (02050) controlling shareholders, directors, and executives plan to collectively reduce their holdings by up to approximately 10.2037 million A-shares [2] Operating Performance - AsiaInfo Technologies (01675) expects to turn cash flow positive by 2025, driven by rapid growth in AI business [2] - Zhaoyi Innovation (03986) issued a profit warning, expecting a net profit of approximately 1.61 billion yuan in 2025, a year-on-year increase of about 46% [2] - MicroPort Medical (00853) issued a profit warning, expecting a net profit of no less than 20 million USD in 2025, turning profitable year-on-year [2]

Core Viewpoint - MicroPort Medical (00853) anticipates turning a profit by the end of the fiscal year ending December 31, 2025, with a projected net profit of no less than $20 million, recovering from an audited net loss of approximately $268 million for the fiscal year ending December 31, 2024 [1] Group 1: Financial Performance - The expected turnaround to profitability is primarily attributed to continuous revenue growth, particularly from overseas operations, which are projected to contribute to a year-on-year increase of approximately 70% [1] - Despite downward pressure on product prices due to domestic industry policies in China, the implementation of cost optimization measures is expected to result in a gross margin improvement of 2-3 percentage points year-on-year [1] Group 2: Operational Efficiency - The company is focusing on deepening lean management practices to enhance operational efficiency, leading to a year-on-year decrease in operating expenses of approximately 10-11% [1] - The disposal of subsidiaries is also expected to contribute positively to the company's overall financial performance [1]

预期扭亏为盈主要归因于本期间内：收入的持续增长，尤其出海业务收入继续贡献同比约70%的高速增 长;尽管中国境内行业政策给产品价格带来下行压力，受益于成本优化举措的落实，毛利率仍同比提升 2~3个百分点;于运营方面持续深化精益管理，提升经营效率，令本集团经营费用同比下降约10~11%;及 附属公司处置为本集团贡献正向收益。 智通财经APP讯，微创医疗(00853)发布公告，预期本集团截至2025年12月31日止年度(本期间)将实现扭 亏为盈，并取得净利润不低于2000万美元(截至2024年12月31日止年度：经审计净亏损约2.68亿美元)。 ...

预期扭亏为盈主要归因于本期间内：(1)收入的持续增长，尤其出海业务收入继续贡献同比约70%的高速 增长；(2)尽管中国境内行业政策给产品价格带来下行压力，受益于成本优化举措的落实，毛利率仍同 比提升2~3个百分点；(3)于运营方面持续深化精益管理，提升经营效率，令集团经营费用同比下降约 10~11%；及(4)附属公司处置为集团贡献正向收益。 格隆汇1月22日丨微创医疗(00853.HK)公告，预期集团截至2025年12月31日止年度(「本期间」)将实现 扭亏为盈，并录得净利润不低于2千万美元(截至2024年12月31日止年度：经审计净亏损约2.68亿美元)。 ...